Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden
· Delayed Price · Currency is SEK 5.90
-0.09 (-1.50%)
At close: Mar 9, 2026
Xbrane Biopharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 152.35 | 198.72 | 238.73 | 57.62 | 10.71 | Upgrade
|
| Revenue | 152.35 | 198.72 | 238.73 | 57.62 | 10.71 | Upgrade
|
| Revenue Growth (YoY) | -23.33% | -16.76% | 314.33% | 438.03% | - | Upgrade
|
| Cost of Revenue | 62.81 | 18.23 | 203.34 | - | - | Upgrade
|
| Gross Profit | 89.55 | 180.5 | 35.39 | 57.62 | 10.71 | Upgrade
|
| Selling, General & Admin | 43.82 | 40.11 | 40.03 | 31.54 | 31.4 | Upgrade
|
| Research & Development | 76.82 | 312.89 | 305.78 | 199.65 | 160.62 | Upgrade
|
| Other Operating Expenses | -2.85 | 30.54 | -13.71 | -20.91 | -4.85 | Upgrade
|
| Operating Expenses | 117.8 | 383.54 | 332.11 | 210.27 | 187.17 | Upgrade
|
| Operating Income | -28.25 | -203.04 | -296.72 | -152.65 | -176.46 | Upgrade
|
| Interest Expense | -15.69 | -33.63 | -18.5 | -2.58 | -2.64 | Upgrade
|
| Interest & Investment Income | - | 0.5 | 2.41 | 0.3 | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | -14.87 | -9.15 | -13.56 | -4.13 | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | -2.39 | -0.06 | -0.01 | -0.01 | Upgrade
|
| Pretax Income | -43.93 | -253.43 | -322.03 | -168.51 | -183.23 | Upgrade
|
| Income Tax Expense | 2.23 | 11.59 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -46.17 | -265.02 | -322.03 | -168.51 | -183.23 | Upgrade
|
| Earnings From Discontinued Operations | 173.41 | -1.2 | -66.14 | -4 | -5.15 | Upgrade
|
| Net Income | 127.24 | -266.22 | -388.17 | -172.51 | -188.38 | Upgrade
|
| Net Income to Common | 127.24 | -266.22 | -388.17 | -172.51 | -188.38 | Upgrade
|
| Shares Outstanding (Basic) | 12 | 10 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 10 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 23.72% | 4184.97% | 12.26% | 8.38% | 30.25% | Upgrade
|
| EPS (Basic) | 10.45 | -27.06 | -1690.32 | -843.34 | -998.04 | Upgrade
|
| EPS (Diluted) | 10.45 | -27.62 | -1690.32 | -843.34 | -998.54 | Upgrade
|
| Free Cash Flow | -250.69 | -134.23 | -413.47 | -205.53 | -247.29 | Upgrade
|
| Free Cash Flow Per Share | -20.59 | -13.64 | -1800.48 | -1004.76 | -1310.16 | Upgrade
|
| Gross Margin | 58.77% | 90.83% | 14.82% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -18.54% | -102.17% | -124.29% | -264.94% | -1647.75% | Upgrade
|
| Profit Margin | 83.52% | -133.97% | -162.60% | -299.41% | -1759.04% | Upgrade
|
| Free Cash Flow Margin | -164.55% | -67.55% | -173.20% | -356.72% | -2309.16% | Upgrade
|
| EBITDA | -13.65 | -193.86 | -287.62 | -145.21 | -171.93 | Upgrade
|
| EBITDA Margin | -8.96% | -97.55% | -120.48% | -252.03% | - | Upgrade
|
| D&A For EBITDA | 14.6 | 9.18 | 9.1 | 7.44 | 4.53 | Upgrade
|
| EBIT | -28.25 | -203.04 | -296.72 | -152.65 | -176.46 | Upgrade
|
| EBIT Margin | -18.54% | -102.17% | -124.29% | -264.94% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.